Log In
Print this Print this

ravidasvir (ASC16, PPI-668)

  Manage Alerts
Collapse Summary General Information
Company Presidio Pharmaceuticals Inc.
DescriptionSecond-generation HCV NS5A protein inhibitor
Molecular Target HCV NS5A protein
Mechanism of ActionHCV non-structural protein 5A inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 infection in treatment-naïve patients; Treat chronic HCV genotype 4 infection; Treat HCV genotype 1 infection
Regulatory Designation
Partner Ascletis Pharmaceuticals Co. Ltd.; Pharco Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today